Drug therapy at discharge
| Overall cohort | Propensity score-matched cohort | |||||||
| PCI group (n=590) | CABG group (n=127) | P values | Standardised difference | PCI group (n=95) | CABG group (n=95) | P values | Standardised difference | |
| Drug therapy at discharge | ||||||||
| ACEIs or ARBs | 387 (65.6) | 58 (45.7) | <0.001 | −0.409 | 61 (64.2) | 41 (43.2) | 0.008 | −0.432 |
| Beta-blockers | 382 (64.8) | 59 (46.5) | <0.001 | −0.375 | 60 (63.2) | 45 (47.4) | 0.082 | −0.322 |
| Aldosterone antagonists | 200 (33.9) | 58 (45.7) | 0.012 | 0.242 | 36 (37.9) | 42 (44.2) | 0.480 | 0.129 |
Per cent (%) in parentheses.
ACEIs, ACE inhibitors; ARBs, angiotensin receptor blockers; CABG, coronary artery bypass graft; HF, heart failure; PCI, percutaneous coronary intervention.